28 December 2017 14:00 GMT
�
TRANSACTION BY PERSON DISCHARGING MANAGERIAL
RESPONSIBILITIES - AMENDMENT
Disclosure under Article 19 of the EU Market Abuse Regulation
�
AstraZeneca PLC (the Company) announces that the notification made in accordance with the requirements of the EU Market Abuse Regulation on 15 December 2017 relating to a change in the beneficial interest in the Company's Ordinary Shares of US$0.25 each of Mr Soriot has been amended, as set out in the revised notification below.
�
|
1 � |
Details of the person discharging managerial responsibilities / person closely associated � |
|||||
|
a) � |
Name � � |
Pascal Soriot � |
||||
|
2 � |
Reason for the notification � |
|||||
|
a) � |
Position/status � � |
Chief Executive Officer |
||||
|
b) � |
Initial notification /Amendment � � |
Amendment � - Previous notification reference number: 00031829 - Effective date of transfer amended from 13 December 2017 - Number of shares transferred amended from 40,148 |
||||
|
3 � |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor � |
|||||
|
a) � |
Name � � |
AstraZeneca PLC |
||||
|
b) � |
LEI � � |
PY6ZZQWO2IZFZC3IOL08 |
||||
|
4 � |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted � � |
|||||
|
a) � |
Description of the financial instrument, type of instrument � Identification code � � |
Ordinary Shares of US$0.25 each in AstraZeneca PLC � � GB0009895292 � |
||||
|
b) � |
Nature of the transaction � � |
Gift of shares to family members for nil consideration |
||||
|
c) � |
Price(s) and volume(s) � � |
�
|
||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
||||
|
e)
|
Date of the transaction
|
27 December 2017 |
||||
|
f)
|
Place of the transaction
|
Outside a trading venue |
||||
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
|
Media Relations |
|
|
|
Esra Erkal-Paler |
UK/Global |
+44 203 749 5638 |
|
Karen Birmingham |
UK/Global |
+44 203 749 5634 |
|
Rob Skelding |
UK/Global |
+44 203 749 5821 |
|
Matt Kent |
UK/Global |
+44 203 749 5906 |
|
Gonzalo Viña |
UK/Global |
+44 203 749 5916 |
|
Jacob Lund |
Sweden |
+46 8 553 260 20 |
|
Michele Meixell |
US |
+1 302 885 2677 |
|
|
|
|
|
Investor Relations |
|
|
|
Thomas Kudsk Larsen |
|
+44 203 749 5712 |
|
Craig Marks |
Finance, Fixed Income, M&A |
+44 7881 615 764 |
|
Henry Wheeler |
Oncology |
+44 203 749 5797 |
|
Mitchell Chan |
Oncology; Other |
+1 240 477 3771 |
|
Christer Gruvris |
Brilinta ; Diabetes |
+44 203 749 5711 |
|
Nick Stone |
Respiratory; Renal |
+44 203 749 5716 |
|
US toll free |
|
+1 866 381 7277 |
Adrian Kemp
Company Secretary
AstraZeneca PLC